EGFR靶向药物西妥昔单抗在结直肠癌治疗中的应用进展  

Prospect of cetuximab in the treatment of colorectal cancer

作　　者：李洪涛[1] 刘宏斌[1] 赵青川[2] 韩晓鹏[1] 朱万坤[1] 苏琳[1] 

机构地区：[1]兰州军区兰州总医院普通外科,730050 [2]第四军医大学西京消化病医院,西安710032

出　　处：《中华消化外科杂志》2013年第7期556-560,共5页Chinese Journal of Digestive Surgery

基　　金：国家基础研究项目（2009eB521705）;国家自然科学基金（30672399、30973410、30971337）

摘　　要：结直肠癌是最常见的恶性肿瘤，随着人类平均寿命的提高，生存环境及生活方式的改变，近年来结直肠癌的发病率呈逐年上升趋势，在发达国家及我国经济发达地区，结直肠癌的发病率已上升至恶性肿瘤的第2位。全球每年新增病例约100万，死亡病例约50万，结直肠癌已经成为全球恶性肿瘤导致死亡的主要原因之一。近年来分子靶向药物的出现使晚期结直肠癌患者的治疗得到了明显的改善，本文就结直肠癌靶向治疗的现状及研究进展做一综述。Colorectal cancer is one of the most common malignant tumors. With the improvement of living condition and peoples＇ life-span, the incidence rate of colorectal cancer has been ascending year by year. In developed countries and devel- oped district of China, colorectal cancer has become the second common malignant tumor. More than one million people were diagnosed as with colorectal cancer, and 500,000 of them died yearly. Colorectal cancer is one of the most common reasons of the death of cancer patients. With the development of molecular targeted agents research, the therapeutic effects for colorectal cancer patients have been improved, and the current status and prospect of targeted therapy for colorectal cancer patients were introduced in this review.

关 键 词：结直肠肿瘤 靶向治疗 

分 类 号：R735[医药卫生—肿瘤]